Next Article in Journal
Stealth Liposomes (PEGylated) Containing an Anticancer Drug Camptothecin: In Vitro Characterization and In Vivo Pharmacokinetic and Tissue Distribution Study
Next Article in Special Issue
Synergistic Effect of Lithocholic Acid with Gentamicin against Gram-Positive Bacteria but Not against Gram-Negative Bacteria
Previous Article in Journal
Mononuclear Transition Metal Cymantrenecarboxylates as Precursors for Spinel-Type Manganites
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 3
10.3390/molecules27031085
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaOXA-23-harboring CRAB in In Vitro PK/PD Model

by
Xingyi Qu
1,2,3,4,†,
Xingchen Bian
1,2,3,5,†,
Yuancheng Chen
3,4,
Jiali Hu
1,2,3,
Xiaolan Huang
1,2,3,
Yu Wang
1,2,3,
Yaxin Fan
1,2,3,
Hailan Wu
1,2,3,
Xin Li
1,2,3,
Yi Li
1,2,3,
Beining Guo
1,2,3,
Xiaofen Liu
1,2,3,* and
Jing Zhang
1,2,3,4,*
1
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China
2
Key Laboratory of Clinical Pharmacology of Antibiotics, Shanghai 200040, China
3
National Health Commission & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
4
Phase I Unit, Huashan Hospital, Fudan University, Shanghai 200040, China
5
Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to the manuscript.
Molecules 2022, 27(3), 1085; https://doi.org/10.3390/molecules27031085
Submission received: 30 December 2021 / Revised: 25 January 2022 / Accepted: 1 February 2022 / Published: 6 February 2022
(This article belongs to the Special Issue New Aspects of Pharmacology and Toxicology of Antibacterial Drugs)
Browse Figures
Versions Notes

Abstract

:
Polymyxin-based combination therapy is commonly used to treat carbapenem-resistant Acinetobacter baumannii (CRAB) infections. In the present study, the bactericidal effect of polymyxin B and minocycline combination was tested in three CRAB strains containing blaOXA-23 by the checkerboard assay and in vitro dynamic pharmacokinetics/pharmacodynamics (PK/PD) model. The combination showed synergistic or partial synergistic effect (fractional inhibitory concentration index ≤0.56) on the tested strains in checkboard assays. The antibacterial activity was enhanced in the combination group compared with either monotherapy in in vitro PK/PD model. The combination regimen (simultaneous infusion of 0.75 mg/kg polymyxin B and 100 mg minocycline via 2 h infusion) reduced bacterial colony counts by 0.9–3.5 log10 colony forming units per milliliter (CFU/mL) compared with either drug alone at 24 h. In conclusion, 0.75 mg/kg polymyxin B combined with 100 mg minocycline via 2 h infusion could be a promising treatment option for CRAB bloodstream infections.

1. Introduction

Bloodstream infections are most common (37/131 studies, 28%) severe infections among reported studies, and Acinetobacter baumannii is the top pathogen (52/131 studies, 38.5% and 4395/11,546 patients, 38%) [1]. The mortality of Acinetobacter baumannii-related bloodstream infections showed an increasing trend in a 10-year prospective study in China [2]. There is an urgent need for rational and effective medication schemes to be developed in clinics. Polymyxins have become a last-resort treatment for multi-drug resistant Gram-negative bacterial infections, including Acinetobacter baumannii [3]. Although higher doses resulted in better therapeutic outcomes, greater incidence of toxicity tended to follow, such as nephrotoxicity and neurotoxicity [4]. The adverse effects limited the clinical use of polymyxins and deficient drug doses may induce the development of polymyxin-resistant Gram-negative bacteria [5]. Polymyxins are concentration-dependent antibiotics [6]. The pharmacokinetics/pharmacodynamics (PK/PD) index of polymyxins is polymyxins’ area under the concentration-time curve (AUC) divided by minimum inhibitory concentration (MIC), which is 7.4–17.6 for 2 log10 colony forming units per milliliter (CFU/mL) decrease against Acinetobacter baumannii in mouse thigh model [7]. In contrast to colistin methanesulfonate (CMS), whose active drug concentration increases slowly in blood after administration, polymyxin B has remarkable advantages in bloodstream infections [8]. Coupled with the fact that heterogeneous resistance of Acinetobacter baumannii occurred when using polymyxin B alone [9,10], polymyxin-based combination therapy is rational and necessary [8].
Minocycline, belonging to tetracyclines, is promising for the treatment of Acinetobacter baumannii infections [11,12,13,14]. Minocycline is a time-dependent antibiotic with a long post-antibiotic effect (PAE), the PK/PD index of which is AUC/MIC, and the PK/PD targets for 1 log10CFU/mL were 23.3 ± 3.7 against Acinetobacter baumannii in in vitro studies [15]. A study initiated by the Antimicrobial Stewardship Program (ASP) found that minocycline was safe and effective for patients infected with multi-drug resistant Acinetobacter baumannii (MDRAB) [16]. Several in vitro and in vivo studies have demonstrated synergistic effects and potential mortality decreases of the combination of polymyxin B and minocycline [17,18,19,20]. Polymyxin B and minocycline combination not only had a partial synergy in checkerboard assay with the fractional inhibitory concentration index (FICI) value of 0.75 [17], but also prolonged the survival time of the lung-infection mice [17,18].
However, most previous studies on the combined efficacy of polymyxin B and minocycline against Acinetobacter baumannii were limited to checkerboard assays and static time-kill curves [18,19,20], rarely considering the dynamic changes of drugs’ pharmacokinetics in the human body. Therefore, the present study simulated the pharmacokinetics of polymyxin B and minocycline against Acinetobacter baumannii bloodstream infection in in vitro dynamic PK/PD models. The bactericidal effects are expected to provide important information for optimizing dosing regimens for this combination against carbapenem-resistant Acinetobacter baumannii (CRAB).

2. Results

2.1. Genetic Information, MICs, and Checkboard Assays

The genetic information of the three strains has been analyzed through whole-genome sequencing [21], as shown in Table 1. The three strains have different multilocus sequence typing (MLST) subtypes, namely, ST195, ST208, and ST191, which were the dominant sequence types in Acinetobacter baumannii [21]. All the three strains had the lpxC and lpxA genes without mutations. The three strains were intermediate to polymyxin B (according to CLSI, M100-S31, 2021) with MICs of 0.5, 0.5, and 0.25 mg/L, respectively (Table 2). All the three strains harboring the tetA gene that encodes resistance to tetracycline were resistant to doxycycline (MICs were 64 mg/L for all the strains), susceptible to minocycline for AB070311 and AB170428, and intermediate for AB162487. The genome annotation revealed that all the strains contained multiple antibiotic resistance genes including OXA-23, OXA-66 encoding the beta-lactamase resistance, which are consistent with the MICs over 16 mg/L for meropenem and doripenem. The three strains also had high MICs for aztreonam (MICs = 64 mg/L) and cefoperazone (MICs > 256 mg/L), which were consistent with the ARO gene, TEM-1, for example.
Checkboard assays showed that one strain (AB162487) had a synergistic effect of polymyxin B and minocycline with a FICI value of 0.375. The other two strains (AB070311 and AB170428) showed partial synergistic effects of polymyxin B and minocycline, and the FICI values were 0.56 (Table 2).

2.2. Dynamic PK/PD Model

2.2.1. Concentration Verification

In the dynamic PK/PD model, the concentrations of polymyxin B (0.75 mg/kg intravenously administration with 2 h infusion) and minocycline (100 mg intravenously administration with 2 h infusion) in the central compartment were within ±30% of the target concentrations (except minocycline at 24 h) as verified by LC-MS/MS (Figure 1).

2.2.2. Time-Kill Curves

The colony counts of the three strains were recorded under different dosing regimens (Figure 2). The single dosing regimen of polymyxin B (pharmacokinetics corresponding to 0.75 mg/kg 2 h infusion in bloodstream infection patients) showed antibacterial activity for the first 2 h, with the colony counts approximately decreased 3–4 log10CFU/mL (range from −3.74 to −3.17 log10CFU/mL). However, the colony count then increased to the initial inoculum level in the following 22 h. The colony counts of single dosing regimen of minocycline (pharmacokinetics corresponding to 100 mg via 2 h infusion in healthy volunteers) resulted 1.6 log10CFU/mL increase in average (ranging from 1.16 to 1.85 log10CFU/mL) in 24 h. Nevertheless, the combination regimen of polymyxin B (0.75 mg/kg, 2 h infusion) and minocycline (100 mg, 2 h infusion) demonstrated significantly enhanced antibacterial activity over a 24 h period, with the colony counts decreasing more than 4 log10CFU/mL at 3 h (below the limit of detection).
As shown in Figure 2, for the combination therapy, despite a rebound occurring after 3 h, the average colony counts were still decreased by 1.3 log10CFU/mL at 24 h compared with initial counts at 0 h (ranging from −1.86 to −0.81 log10CFU/mL), showing superior antibacterial activity and 0.9–3.5 log10CFU/mL compared with either drug alone at 24 h [22].

2.2.3. PK/PD Calculation

The AUCs were 19.07 and 8.61 mg·h/L for polymyxin B (0.75 mg/kg infusion) and minocycline (100 mg infusion), respectively. The AUC/MICs for polymyxin B and minocycline in monotherapy or combination therapy were calculated in Table 3. In checkboard assays, polymyxin B and minocycline combination decreased MICs by 2–8 folds more than monotherapy did. Therefore, AUC/MIC achieved higher values after combination comparing with that of monotherapy.

3. Discussion

Polymyxin-based combination therapies would be effective treatments for CRAB infections, with higher clinical response rates compared with non-polymyxin based therapies [23]. Zhang et al. [20] performed checkerboard assays and static time-kill curves, and showed that polymyxin B and minocycline had a synergistic or additive effect on pan-drug-resistant Acinetobacter baumannii, with FICI values ≤0.5 (44%) or in the range of 0.5–1 (48%). Another study conducted animal experiments and observed the four-day survival rate of mice. Polymyxin B and minocycline combination extended the survival time in a neutropenic murine pneumonia model [18]. Maya et al. reported a triple therapy combination against CRAB using an in vitro PK/PD model [24] which demonstrated that minocycline (700 mg loading dose plus 350 mg q12h) and polymyxin B (0.25 mg/kg) combined with sulbactam (9 g, continuous infusion in 24 h) could maintain a bactericidal effect for 96 h with no bacterial regrowth and minimal resistance development [24].
All three strains selected were intermediated to polymyxin B, and two of them were susceptible to minocycline, with one intermediate to minocycline. The MICs of polymyxin B were equal to the MIC90 (0.5 mg/L) of 262 Acinetobacter baumannii strains from more than 30 teaching hospitals in China [25]. The susceptibility range of minocycline was 20–62.5% against Acinetobacter baumannii in Chinese bloodstream infection patients [26]. Hence, all the three strains were typically representative for Acinetobacter baumannii. At the same time, the selected strains were classified as ST195, ST208, and ST191, respectively, which were the typical sequence type isolated from sputum, blood, or urine in a previous study [21]. Meanwhile, the three strains all have blaOXA-23, which has been considered as the most possible reason for carbapenem resistance in Acinetobacter baumannii isolates [21]. For AB070311 and AB170428, Bian et al. [27] performed similar in vitro PK/PD experiments using colistin and sulbactam: 1 mg/L of colistin and 1 g of sulbactam effectively reduced bacterial counts by 2 log10CFU/mL in 24 h. We simulated the pharmacokinetics of polymyxin B and minocycline and investigated the antibacterial effect of the combination regimen. Satisfactory results (0.81–1.86 log10CFU/mL decrease at 24 h) showed synergy or partial synergy of 0.75 mg/kg polymyxin B and 100 mg minocycline combination against three CRABs in our study. Therefore, polymyxin B combined with minocycline can also be considered as an alternative effective combination approach for treating CRAB. As for PK/PD calculations, MICs in combination are considered more reasonable than MICs in monotherapy. When two antimicrobial agents were used in combination, they had a combined PK/PD index [28]. The tested three strains all achieved the PK/PD target of 2 log10CFU/mL reduction (>17.6) for polymyxin B in monotherapy [7]. Unfortunately, none of them reached the PK/PD target 23.3 ± 3.7 for minocycline in monotherapy. In combination, not only the AUC/MICs were achieved for polymyxin B, but also AB070311 and AB170428 reached the AUC/MIC target for minocycline.
Although pharmacokinetic parameters of minocycline were obtained from Chinese healthy subjects [29], there were similar pharmacokinetics between patients and healthy subjects [30,31,32]. Additionally, both polymyxin B and minocycline had similar T1/2 (~12 h) in adult patients [30,33], providing more advantageous combination therapy with similar pharmacokinetic profiles. The extended infusion time was taken into consideration in the present study, and a 2 h infusion rather than a single injection was performed. The pharmacokinetic simulations of both drugs were based on two-compartment models with parameters of V1, K21, α, and β, so the simulated concentrations were more accurate. Our study demonstrated that a combined infusion of 100 mg minocycline and 0.75 mg/kg polymyxin B via a 2 h infusion in humans could lead to the reduction of bacterial burden over 24 h against three CRAB isolates. However, there were several limitations. Firstly, a single dose was performed, and the bactericidal effect of multiple doses needs further validation. Secondly, our study simulated a combination regimen that both drugs were infused simultaneously rather than sequentially, while both approaches could apply in clinics. Whether sequential infusion could also achieve bacterial burden reduction also needs further investigation. Lastly, the host immune system was not taken into account; there could be an underestimation in the extrapolation of our results to patients with a normal immune system. Therefore, the enhanced bactericidal effects of polymyxin B combined with minocycline in the in vitro PK/PD model still needs to be validated in the clinic.
Possible mechanisms could be explained for the synergy between the combination of polymyxin and minocycline. Firstly, polymyxin B is able to destroy bacterial cell envelope [34], which makes it easier for minocycline to enter into cells and bind to the 30S ribosomal subunit [35], thus inhibiting protein synthesis. Secondly, polymyxin B can interfere with the minocycline efflux pump, resulting in increased intracellular concentrations of minocycline and bactericidal activity [18]. Furthermore, the possible PAE may play an important role in this combination. The PAE of tetracyclines was >4 h against Enterobacteriaceae, although unclear against Acinetobacter baumannii [36,37,38].
Other than the synergistic effect of the polymyxin B and minocycline, the combination may have other advantages. This combination therapy could prolong the survival time of lung-infection mice [18]. Nephrotoxicity and neurotoxicity are the main limitation of polymyxin B application [4,39]. The incidence of polymyxin B-induced neurotoxicity-related adverse reactions, including perioral paresthesia, dizziness, and numbness of extremities, is much higher in healthy subjects (>70%) [40]. Minocycline is reported to have strong antioxidant activity through chelating with mitochondrial iron [41], which could inhibit the production of reactive oxygen species (ROS) induced by polymyxins and up-regulate the activities of superoxide dismutase (SOD) and catalase (CAT) to enhance antioxidant capacity of nerve cells [42], thus reducing the polymyxins-induced neurotoxicity. Hence, minocycline was tested for a polymyxin-based combination not only because its antibacterial activity [43], but also because its superiority in alleviating adverse reactions, such as the neurotoxicity of polymyxins [42,44]. Of note, the combination could achieve 0.9–3.5 log10CFU/mL with a much lower dose of polymyxin B (1.25–1.5 mg/kg, q12 h [45]), which could be expected to reduce the adverse effect of polymyxin B. However, the safety of the combination in clinics still needs further investigation.

4. Materials and Methods

Polymyxin B (USP, Lot No. R046V0, 1 mg polymyxin B contained 0.734 mg polymyxin B1, 0.086 mg B1-Ile, and 0.090 mg polymyxin B2) and minocycline hydrochloride (Meilunbio®, Dalian, China, MB1477-S, purity 98.9%) were used in this study. Three clinical strains of CRAB isolated from sputum, urine, and blood were studied, detailed clinical information has been described previously [27]. Whole-genome sequencing was employed to investigate the resistant genes and MLST type. Briefly, the genomic DNA was extracted by a Genomic DNA Purification Kit (Tiangen, Beijing, China) according to the production protocol. Sequencing was performed on Illumina Hiseq2500 (Illumina, San Diego, CA, USA). A draft genome was assembled using Velvet (Ver 1.0.15), and resistant genes were searched against “CARD, https://card.mcmaster.ca/” database (accessed on 1 October 2021). Multilocus sequence typing (MLST) was performed according to the Oxford scheme. After comparing sequences to the PubMLST database for Acinetobacter baumannii (http://pubmlst.org/abaumannii/ accessed on 1 October 2021), each strain was assigned to the appropriate sequence type.
Minimal inhibitory concentrations (MICs) were determined according to the Clinical and Laboratory Standards Institute (CLSI) guidelines and interpreted according to CLSI breakpoints (CLSI M100-S31, 2021). Checkerboard assays were conducted the same way as that reported by Bian et al. [27]. Synergy was determined by FICI, which is calculated as follows: FICI = MIC PMB when combined with MINO/MIC PMB alone + MIC MINO when combined with PMB/MIC MINO alone [46]. FICI ≤ 0.5 was assigned as synergy, 0.5 < FICI ≤ 0.75 as partial synergy, 0.75 < FICI ≤ 1 as additive effect, and >1 indicated indifferent or antagonistic effect [46].
The in vitro PK/PD model was conducted as previously published [27]. Briefly, the volume of Cation-Adjusted Muller–Hinton Broth (CAMHB) medium in the central compartment was maintained at 200 mL. The initial bacterial inoculum was approximately 6 log10CFU/mL and was pre-cultured for 1 h before dosing. Two reservoirs containing CAMHB or CAMHB with polymyxin B and minocycline were connected to a peristaltic pump (controlled by WinLIN 3.2 software) and used to simulate drug concentrations in the central compartment (as shown in Figure 3).
The bacterial samples were taken with disposable sterile syringe at 0, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after the start of infusion for colony counting and concentration validation. The limit of detection for colony counts was 2 log10CFU/mL. The dose regimens of single drug or combination of 0.75 mg/kg via a 2 h infusion of polymyxin B, and 100 mg via a 2 h infusion of minocycline were simulated by a two-compartment model, based on the pharmacokinetics from Chinese bloodstream infection patients or healthy volunteers [29,47]. Each regimen for each bacterial strain was performed three times in parallel. Samples for concentration validation were kept in a −80 °C refrigerator until analysis. Both polymyxin B and minocycline concentrations were determined using previously validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods [48,49].
For PK/PD calculation, the AUCs of polymyxin B and minocycline were calculated based on the drug concentrations under different dosage regimens. Then, the PK/PD parameters were obtained from AUC of each drug divided by its MIC alone and MIC in combination when FICI reached the minimum.

5. Conclusions

Polymyxin B and minocycline combination showed a synergistic or partial synergistic effect against blaOXA-23 CRAB strains. The in vitro PK/PD model showed that the dosing regimen of 0.75 mg/kg polymyxin B combined with 100 mg minocycline via a 2 h infusion could be a promising treatment option for CRAB bloodstream infections.

Author Contributions

Conceptualization, X.Q. and X.L. (Xiaofen Liu); data curation, X.Q.; formal analysis, X.Q. and X.L. (Xiaofen Liu); funding acquisition, J.Z.; investigation, X.Q. and X.L. (Xiaofen Liu); methodology, J.H., X.H., and X.L. (Xiaofen Liu); project administration, X.L. (Xiaofen Liu); resources, Y.W., Y.F., H.W., X.L. (Xin Li), and B.G.; software, Y.C. and Y.L.; supervision, X.B. and X.L. (Xiaofen Liu); validation, X.Q. and X.B.; visualization, X.Q. and X.B.; writing—review and editing, X.B. and X.L. (Xiaofen Liu) All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (grant number 82173896) and the Shanghai Municipal Science and Technology Commission (grant number 19411964900).

Institutional Review Board Statement

The clinical trial (registration number: NCT01940731) has been approved by the Huashan Institutional Review Board affiliated to Fudan University. Bacterial samples were retrieved from The Culture Collection of Institute of Antibiotics, Huashan Hospital. The Informed Consent Form was waived by the Huashan Institutional Review Board if using strains for further study from The Culture Collection. Personal privacy was not involved in this study.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflict of interests.

References

  1. Savoldi, A.; Carrara, E.; Piddock, L.J.V.; Franceschi, F.; Ellis, S.; Chiamenti, M.; Bragantini, D.; Righi, E.; Tacconelli, E. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: A systematic review of clinical studies. BMC Infect. Dis. 2021, 21, 545. [Google Scholar] [CrossRef] [PubMed]
  2. Jin, L.; Zhao, C.; Li, H.; Wang, R.; Wang, Q.; Wang, H. Clinical profile, prognostic factors, and outcome prediction in hospitalized patients with bloodstream infection: Results from a 10-year prospective multicenter study. Front. Med. 2021, 8, 629671. [Google Scholar] [CrossRef] [PubMed]
  3. Peleg, A.Y.; Hooper, D.C. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med. 2010, 362, 1804–1813. [Google Scholar] [CrossRef] [PubMed]
  4. Falagas, M.E.; Kasiakou, S.K. Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit. Care 2006, 10, R27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Velkov, T.; Dai, C.; Ciccotosto, G.D.; Cappai, R.; Hoyer, D.; Li, J. Polymyxins for CNS infections: Pharmacology and neurotoxicity. Pharmacol. Ther. 2018, 181, 85–90. [Google Scholar] [CrossRef]
  6. Tam, V.H.; Schilling, A.N.; Vo, G.; Kabbara, S.; Kwa, A.L.; Wiederhold, N.P.; Lewis, R.E. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2005, 49, 3624–3630. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Cheah, S.E.; Wang, J.; Nguyen, V.T.; Turnidge, J.D.; Li, J.; Nation, R.L. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: Smaller response in lung infection. J. Antimicrob. Chemother. 2015, 70, 3291–3297. [Google Scholar]
  8. Nang, S.C.; Azad, M.A.K.; Velkov, T.; Zhou, Q.T.; Li, J. Rescuing the last-line polymyxins: Achievements and challenges. Pharmacol. Rev. 2021, 73, 679–728. [Google Scholar] [CrossRef]
  9. Ma, X.; He, Y.; Yu, X.; Cai, Y.; Zeng, J.; Cai, R.; Lu, Y.; Chen, L.; Chen, C.; Huang, B. Ceftazidime/avibactam improves the antibacterial efficacy of polymyxin B against polymyxin b heteroresistant KPC-2-producing Klebsiella pneumoniae and hinders emergence of resistant subpopulation in vitro. Front. Microbiol. 2019, 10, 2029. [Google Scholar] [CrossRef]
  10. Charretier, Y.; Diene, S.M.; Baud, D.; Chatellier, S.; Santiago-Allexant, E.; van Belkum, A.; Guigon, G.; Schrenzel, J. Colistin heteroresistance and involvement of the PmrAB regulatory system in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2018, 62, e00788-18. [Google Scholar] [CrossRef] [Green Version]
  11. Lashinsky, J.N.; Henig, O.; Pogue, J.M.; Kaye, K.S. Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: A review. Infect. Dis. Ther. 2017, 6, 199–211. [Google Scholar] [CrossRef] [Green Version]
  12. Bishburg, E.; Bishburg, K. Minocycline—An old drug for a new century: Emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int. J. Antimicrob. Agents 2009, 34, 395–401. [Google Scholar] [CrossRef]
  13. Greig, S.L.; Scott, L.J. Intravenous minocycline: A review in Acinetobacter infections. Drugs 2016, 76, 1467–1476. [Google Scholar] [CrossRef] [PubMed]
  14. Garrido-Mesa, N.; Zarzuelo, A.; Gálvez, J. Minocycline: Far beyond an antibiotic. Br. J. Pharmacol. 2013, 169, 337–352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Alfouzan, W.A.; Noel, A.R.; Bowker, K.E.; Attwood, M.L.G.; Tomaselli, S.G.; MacGowan, A.P. Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. Int. J. Antimicrob. Agents 2017, 50, 715–717. [Google Scholar] [CrossRef] [PubMed]
  16. Goff, D.A.; Bauer, K.A.; Mangino, J.E. Bad bugs need old drugs: A stewardship program’s evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections. Clin. Infect. Dis. 2014, 59 (Suppl. S6), S381–S387. [Google Scholar] [CrossRef] [PubMed]
  17. He, S.; He, H.; Chen, Y.; Chen, Y.; Wang, W.; Yu, D. In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii. Front. Microbiol. 2015, 6, 507. [Google Scholar] [CrossRef] [PubMed]
  18. Bowers, D.R.; Cao, H.; Zhou, J.; Ledesma, K.R.; Sun, D.; Lomovskaya, O.; Tam, V.H. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob. Agents Chemother. 2015, 59, 2720–2725. [Google Scholar] [CrossRef] [Green Version]
  19. Aranzana-Climent, V.; Buyck, J.M.; Smani, Y.; Pachón-Diaz, J.; Marchand, S.; Couet, W.; Grégoire, N. Semi-mechanistic PK/PD modelling of combined polymyxin B and minocycline against a polymyxin-resistant strain of Acinetobacter baumannii. Clin. Microbiol. Infect. 2020, 26, 1254.e9–1254.e15. [Google Scholar] [CrossRef] [Green Version]
  20. Zhang, Y.; Chen, F.; Sun, E.; Ma, R.; Qu, C.; Ma, L. In vitro antibacterial activity of combinations of fosfomycin, minocycline and polymyxin B on pan-drug-resistant Acinetobacter baumannii. Exp. Ther. Med. 2013, 5, 1737–1739. [Google Scholar] [CrossRef] [Green Version]
  21. Bian, X.; Liu, X.; Zhang, X.; Li, X.; Zhang, J.; Zheng, H.; Song, S.; Li, X.; Feng, M. Epidemiological and genomic characteristics of Acinetobacter baumannii from different infection sites using comparative genomics. BMC Genom. 2021, 22, 530. [Google Scholar] [CrossRef]
  22. LaPlante, K.L.; Rybak, M.J.; Leuthner, K.D.; Chin, J.N. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Antimicrob. Agents Chemother. 2006, 50, 1298–1303. [Google Scholar] [CrossRef] [Green Version]
  23. Lyu, C.; Zhang, Y.; Liu, X.; Wu, J.; Zhang, J. Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis. BMC Infect. Dis. 2020, 20, 296. [Google Scholar] [CrossRef] [Green Version]
  24. Beganovic, M.; Daffinee, K.E.; Luther, M.K.; LaPlante, K.L. Minocycline alone and in combination with polymyxin b, meropenem, and sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 2021, 65, e01680-20. [Google Scholar] [CrossRef] [PubMed]
  25. Bian, X.; Liu, X.; Hu, F.; Feng, M.; Chen, Y.; Bergen, P.J.; Li, J.; Li, X.; Guo, Y.; Zhang, J. Pharmacokinetic/pharmacodynamic based breakpoints of polymyxin B for bloodstream infections caused by multidrug-resistant gram-negative pathogens. Front. Pharmacol. 2022, 12, 785893. [Google Scholar] [CrossRef] [PubMed]
  26. Duan, N.; Sun, L.; Huang, C.; Li, H.; Cheng, B. Microbial distribution and antibiotic susceptibility of bloodstream infections in different intensive care units. Front. Microbiol. 2021, 12, 792282. [Google Scholar] [CrossRef]
  27. Bian, X.; Liu, X.; Feng, M.; Bergen, P.J.; Li, J.; Chen, Y.; Zheng, H.; Song, S.; Zhang, J. Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 2021, 57, 106271. [Google Scholar] [CrossRef] [PubMed]
  28. Bian, X.; Liu, X.; Chen, Y.; Chen, D.; Li, J.; Zhang, J. Dose optimization of colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 2019, 63, e01989-18. [Google Scholar] [CrossRef] [Green Version]
  29. He, J.; Liu, S.; Xia, P.; Chen, Y.; Tang, M.; Dai, Q.; Xiong, L. Pharmacokinetics of single and multiple intravenous doses of minocycline hydrochloride. Chin. J. New Drugs 2006, 15, 824–827. [Google Scholar]
  30. Welling, P.G.; Shaw, W.R.; Uman, S.J.; Tse, F.L.; Craig, W.A. Pharmacokinetics of minocycline in renal failure. Antimicrob. Agents Chemother. 1975, 8, 532–537. [Google Scholar] [CrossRef] [Green Version]
  31. Macdonald, H.; Kelly, R.G.; Allen, E.S.; Noble, J.F.; Kanegis, L.A. Pharmacokinetic studies on minocycline in man. Clin. Pharmacol. Ther. 1973, 14, 852–861. [Google Scholar] [CrossRef] [PubMed]
  32. MINOCIN® Minocycline for Injection 100 mg/vial. Available online: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa (accessed on 1 January 2022).
  33. Kubin, C.J.; Nelson, B.C.; Miglis, C.; Scheetz, M.H.; Rhodes, N.J.; Avedissian, S.N.; Cremers, S.; Yin, M.T. Population pharmacokinetics of intravenous polymyxin B from clinical samples. Antimicrob. Agents Chemother. 2018, 62, e01493-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Trimble, M.J.; Mlynárčik, P.; Kolář, M.; Hancock, R.E. Polymyxin: Alternative mechanisms of action and resistance. Cold Spring Harb. Perspect. Med. 2016, 6, a025288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Asadi, A.; Abdi, M.; Kouhsari, E.; Panahi, P.; Sholeh, M.; Sadeghifard, N.; Amiriani, T.; Ahmadi, A.; Maleki, A.; Gholami, M. Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: Back to the future. J. Glob. Antimicrob. Resist. 2020, 22, 161–174. [Google Scholar] [CrossRef] [PubMed]
  36. Morozumi, M.; Okada, T.; Tajima, T.; Ubukata, K.; Iwata, S. Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae. Int. J. Antimicrob. Agents 2017, 50, 255–257. [Google Scholar] [CrossRef] [PubMed]
  37. Athamna, A.; Athamna, M.; Medlej, B.; Bast, D.J.; Rubinstein, E. In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J. Antimicrob. Chemother. 2004, 53, 609–615. [Google Scholar] [CrossRef] [Green Version]
  38. Zhanel, G.G.; Homenuik, K.; Nichol, K.; Noreddin, A.; Vercaigne, L.; Embil, J.; Gin, A.; Karlowsky, J.A.; Hoban, D.J. The glycylcyclines: A comparative review with the tetracyclines. Drugs 2004, 64, 63–88. [Google Scholar] [CrossRef] [PubMed]
  39. Zavascki, A.P.; Nation, R.L. Nephrotoxicity of polymyxins: Is there any difference between colistimethate and polymyxin B? Antimicrob. Agents Chemother. 2017, 61, e02319-16. [Google Scholar] [CrossRef] [Green Version]
  40. Liu, X.; Chen, Y.; Yang, H.; Li, J.; Yu, J.; Yu, Z.; Cao, G.; Wu, X.; Wang, Y.; Wu, H.; et al. Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects. J. Infect. 2021, 82, 207–215. [Google Scholar] [CrossRef]
  41. Hu, J.; Kholmukhamedov, A.; Lindsey, C.C.; Beeson, C.C.; Jaeschke, H.; Lemasters, J.J. Translocation of iron from lysosomes to mitochondria during acetaminophen-induced hepatocellular injury: Protection by starch-desferal and minocycline. Free Radic. Biol. Med. 2016, 97, 418–426. [Google Scholar] [CrossRef] [Green Version]
  42. Dai, C.; Ciccotosto, G.D.; Cappai, R.; Wang, Y.; Tang, S.; Xiao, X.; Velkov, T. Minocycline attenuates colistin-induced neurotoxicity via suppression of apoptosis, mitochondrial dysfunction and oxidative stress. J. Antimicrob. Chemother. 2017, 72, 1635–1645. [Google Scholar] [CrossRef] [Green Version]
  43. Fragkou, P.C.; Poulakou, G.; Blizou, A.; Blizou, M.; Rapti, V.; Karageorgopoulos, D.E.; Koulenti, D.; Papadopoulos, A.; Matthaiou, D.K.; Tsiodras, S. The Role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: A systematic review of clinical evidence. Microorganisms 2019, 7, 159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Dai, C.; Xiao, X.; Li, J.; Ciccotosto, G.D.; Cappai, R.; Tang, S.; Schneider-Futschik, E.K.; Hoyer, D.; Velkov, T.; Shen, J. Molecular mechanisms of neurotoxicity induced by polymyxins and chemoprevention. ACS Chem. Neurosci. 2019, 10, 120–131. [Google Scholar] [CrossRef] [PubMed]
  45. Tsuji, B.T.; Pogue, J.M.; Zavascki, A.P.; Paul, M.; Daikos, G.L.; Forrest, A.; Giacobbe, D.R.; Viscoli, C.; Giamarellou, H.; Karaiskos, I.; et al. International consensus guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019, 39, 10–39. [Google Scholar] [PubMed]
  46. Neu, H.C. Mecillinam-an amidino penicillin which acts synergistically with other beta-lactam compounds. J. Antimicrob. Chemother. 1977, 3 (Suppl. SB), 43–52. [Google Scholar] [CrossRef]
  47. Zhang, J.; Zhang, S.; Sun, Z.; Han, B.; Kong, Y.; Zhou, L.; Zhu, Z.; Luo, Y.; Zhang, X. Population pharmacokinetics of polymyxin B in patients with sepsis. Chin. Pharm. J. 2021, 56, 744–748. [Google Scholar]
  48. Liu, X.; Yu, Z.; Wang, Y.; Wu, H.; Bian, X.; Li, X.; Fan, Y.; Guo, B.; Zhang, J. Therapeutic drug monitoring of polymyxin B by LC-MS/MS in plasma and urine. Bioanalysis 2020, 12, 845–855. [Google Scholar] [CrossRef]
  49. Patel, D.S.; Sharma, N.; Patel, M.C.; Patel, B.N.; Shrivastav, P.S.; Sanyal, M. Analysis of a second-generation tetracycline antibiotic minocycline in human plasma by LC-MS/MS. Bioanalysis 2011, 3, 2177–2194. [Google Scholar] [CrossRef] [PubMed]
Molecules 27 01085 g001 550
Figure 1. Comparison of target concentrations in human subjects and measured concentrations in the central compartment of in vitro PK/PD model. Red lines: target concentrations in vitro; blue lines: measured concentrations; error limit (red): ±30% of target concentrations.
Figure 1. Comparison of target concentrations in human subjects and measured concentrations in the central compartment of in vitro PK/PD model. Red lines: target concentrations in vitro; blue lines: measured concentrations; error limit (red): ±30% of target concentrations.
Molecules 27 01085 g001
Molecules 27 01085 g002 550
Figure 2. Time-kill curves of polymyxin B and minocycline alone and in combination against CRAB strains in a dynamic PK/PD model. (A): Time-kill curves of AB070311, (B): time-kill curves of AB170428, (C): time-kill curves of AB162487, (D): colony counts changed in the range of 0–24 h; red lines or column: bacterial growth curve; blue lines or column: minocycline 100 mg via 2 h infusion; orange lines or column: polymyxin B 0.75 mg/kg via 2 h infusion; purple lines or column: minocycline 100 mg combined polymyxin B 0.75 mg/kg via 2 h infusion; dash line: the detection limit.
Figure 2. Time-kill curves of polymyxin B and minocycline alone and in combination against CRAB strains in a dynamic PK/PD model. (A): Time-kill curves of AB070311, (B): time-kill curves of AB170428, (C): time-kill curves of AB162487, (D): colony counts changed in the range of 0–24 h; red lines or column: bacterial growth curve; blue lines or column: minocycline 100 mg via 2 h infusion; orange lines or column: polymyxin B 0.75 mg/kg via 2 h infusion; purple lines or column: minocycline 100 mg combined polymyxin B 0.75 mg/kg via 2 h infusion; dash line: the detection limit.
Molecules 27 01085 g002
Molecules 27 01085 g003 550
Figure 3. Experimental apparatus and process diagram.
Figure 3. Experimental apparatus and process diagram.
Molecules 27 01085 g003
Table
Table 1. Genetic information of tested CRAB strains.
Table 1. Genetic information of tested CRAB strains.
ARO NameAB070311AB170428AB162487Antimicrobial Agents’ Classes
lpxC√√√peptide antibiotic
lpxA√√√
tetA√√√glycylcycline; tetracycline antibiotic
tetR√√√
adeA√√√
adeB√√√
adeC√√√
adeR√√√
adeS√√√
adeF√√√tetracycline antibiotic; fluoroquinolone antibiotic
adeG√√√
adeH√√√
adeL√√√
adeN√ tetracycline antibiotic; fluoroquinolone antibiotic; cephalosporin; macrolide antibiotic; carbapenem; rifamycin antibiotic; lincosamide antibiotic; diaminopyrimidine antibiotic; phenicol antibiotic; penem
adeI√√√
adeJ√√√
adeK√√√
MexK√√√tetracycline antibiotic; triclosan; macrolide antibiotic
rpsJ√√√tetracycline antibiotic
OXA-66√√√cephalosporin; penam
OXA-366 √
OXA-23√√√
TEM-1 √√cephalosporin; penam; penem; monobactam
Acinetobacter baumannii OprD conferring resistance to imipenem√√√cephalosporin; penam; penem; monobactam; carbapenem; cephamycin
carO√√√carbapenem
ADC-61 √√cephalosporin
ADC-78√
MLSTST195ST208ST191
ARO, Antibiotic Resistance Ontology; tet, tigecycline resistance gene; MLST, multilocus sequence typing.
Table
Table 2. MICs and FICI values of tested CRAB strains.
Table 2. MICs and FICI values of tested CRAB strains.
Antimicrobial AgentsAB070311AB170428AB162487
polymyxin B 0.5 (I)0.5 (I)0.25 (I)
minocycline4 (S)4 (S)8 (I)
doxycycline64 (R)64 (R)64 (R)
meropenem64 (R)16 (R)16 (R)
doripenem64 (R)32 (R)16 (R)
aztreonam *646464
cefoperazone *>256>256>256
sulbactam *161616
FICI(PMB/MINO)0.560.560.375
CRAB, carbapenem-resistant Acinetobacter baumannii; MIC, minimal inhibitory concentration, presented in mg/L; FICI(PMB/MINO), fractional inhibitory concentration index of polymyxin B and minocycline combination; S, susceptibility; I, intermediacy; R: resistance. *: CLSI does not provide susceptibility breakpoints for aztreonam, cefoperazone, and sulbactam.
Table
Table 3. PK/PD calculations of tested CRAB strains.
Table 3. PK/PD calculations of tested CRAB strains.
AB070311AB170428AB163560
MICAUC/MICMICAUC/MICMICAUC/MIC
PMB Alone0.5038.140.5038.140.2576.28
PMB Combined with MINO0.2576.280.2576.280.06305.12
MINO Alone4.002.154.002.158.001.08
MINO Combined with PMB0.2534.420.2534.421.008.61
MINO: minocycline; PMB: polymyxin B.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Qu, X.; Bian, X.; Chen, Y.; Hu, J.; Huang, X.; Wang, Y.; Fan, Y.; Wu, H.; Li, X.; Li, Y.; et al. Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaOXA-23-harboring CRAB in In Vitro PK/PD Model. Molecules 2022, 27, 1085. https://doi.org/10.3390/molecules27031085

AMA Style

Qu X, Bian X, Chen Y, Hu J, Huang X, Wang Y, Fan Y, Wu H, Li X, Li Y, et al. Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaOXA-23-harboring CRAB in In Vitro PK/PD Model. Molecules. 2022; 27(3):1085. https://doi.org/10.3390/molecules27031085

Chicago/Turabian Style

Qu, Xingyi, Xingchen Bian, Yuancheng Chen, Jiali Hu, Xiaolan Huang, Yu Wang, Yaxin Fan, Hailan Wu, Xin Li, Yi Li, and et al. 2022. "Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaOXA-23-harboring CRAB in In Vitro PK/PD Model" Molecules 27, no. 3: 1085. https://doi.org/10.3390/molecules27031085

APA Style

Qu, X., Bian, X., Chen, Y., Hu, J., Huang, X., Wang, Y., Fan, Y., Wu, H., Li, X., Li, Y., Guo, B., Liu, X., & Zhang, J. (2022). Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaOXA-23-harboring CRAB in In Vitro PK/PD Model. Molecules, 27(3), 1085. https://doi.org/10.3390/molecules27031085

Article Metrics

Back to TopTop